Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 22, 2016

Primary Completion Date

May 20, 2019

Study Completion Date

June 22, 2023

Conditions
Non-Small-Cell Lung Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab 200 mg

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Pemetrexed

IV infusion

DIETARY_SUPPLEMENT

Folic acid 350-1000 μg

Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

DIETARY_SUPPLEMENT

Vitamin B12 1000 μg

Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

DRUG

Dexamethasone 4 mg

For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

DRUG

Saline solution

IV infusion

Trial Locations (10)

460-0001

National Hospital Organization Nagoya Medical Center ( Site 0324), Nagoya

830-0011

Kurume University Hospital ( Site 0326), Kurume

673-8558

Hyogo Cancer Center ( Site 0325), Akashi

920-8641

Kanazawa University Hospital ( Site 0328), Kanazawa

573-1191

Kansai Medical University Hospital ( Site 0313), Hirakata

411-8777

Shizuoka Cancer Center Hospital and Research Institute ( Site 0322), Sunto-gun

791-0280

National Hospital Organization Shikoku Cancer Center ( Site 0303), Matsuyama

700-8558

Okayama University Hospital ( Site 0327), Okayama

104-0045

National Cancer Center Hospital ( Site 0301), Tokyo

135-8550

The Cancer Institute Hospital of JFCR ( Site 0323), Tokyo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03950674 - Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | Biotech Hunter | Biotech Hunter